PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE
Abstract
Authors
V Papagianopoulou A Christodoulopoulou A Bracco I Yfantopoulos